www.paris-nash.org
Dear Colleagues, We are delighted to announce the 4th Paris NASH Meeting to be held on July 5-6 th 2018. This international academic meeting is aimed to do a deep-dive into many aspects of NASH and to deliver scientific innovations that are not covered in other meetings. This year, beside US, the faculty has been extended to a large panel of European key opinion leaders, achieving science from both sides of the Atlantic. In order to have more time for interactive discussion, the format of the meeting is now two days long with a limited number of sessions. Working interactive sessions and abstract-driven programming will also be provided. As in previous years, the meeting will be held at the venerable Institut Pasteur in the city center of Paris. Hoping meeting you in Paris next summer. Sincerely Lawrence Serfaty www.paris-nash.org
THURSDAY, JULY 5, 2018 08:00-08:30 am CONFERENCE OPENING 08:30-08:35 am Welcome remarks - Lawrence Serfaty (France) 08:35-08:45 am Inauguration Address - Stanislas Pol (France) 08:45-10:15 am SESSION 1 NASH EPIDEMIOLOGY AND PUBLIC HEALTH Chairs: Patrick Marcellin (France) and Michael Trauner (Austria) 08:45-09:05 am The value proposition of NASH therapy on the burden of disease related to obesity. Homie Razavi (USA) 09:05-09:25 am The evolution of NASH from childhood to adulthood. Joel Lavine (USA) 09:25-09:45 am 09:45-10:15 am Discussion What is needed to put NASH on the radar for WHO- lessons learned from viral hepatitis. Jean-Michel Pawlotsky (France) and Speaker TBC 10:15-10:45 am COFFEE BREAK AND POSTERS 10:45-12:15 pm SESSION 2 CARDIO-METABOLIC MORBIDITY AND MORTALITY DUE TO NAFLD Chairs: Scott Friedman (USA) and Fabio Marra (Italy) 10:45-11:05 am Does reversal of NASH reverse cardiovascular risk? Bart Staels (France) 11:05-11:25 am Is type 2 diabetes and NASH the same disease affecting different organs? Bertrand Cariou (France) 11:25-11:45 am Acceleration of cardiometabolic disease after liver transplantation for NASH. Mohammad Siddiqui (USA) 11:45-12:15 pm Discussion 12:15-12:45 pm SESSION 3 CLINICAL STATE OF THE ART LECTURE Chair: Philippe Mathurin (France) 12:15-12:45 pm The pathophysiological, clinical and regulatory implications of alcohol consumption in Non Alcoholic SteatoHepatitis. Arun Sanyal (USA)
12:45-02:00 pm LUNCH AND INDUSTRY SATELLITE SYMPOSIUM 02:00-03:50 pm SESSION 4 PRECISION MEDICINE FOR NASH Chairs: Quentin Anstee (United Kingdom) and Lawrence Serfaty (France) 02:00-02:20 pm Molecular markers of disease progression in NASH. Jean-François Dufour (Switzerland) 02:20-02:40 pm Phenotyping NAFLD based on whole body morphometry. Olof Dahlqvist Leinhard (Sweden) 02:40-03:00 pm Phenotyping NAFLD based on the gut microbiome. Karim Dabbagh (USA) 03:00-03:20 pm The potential use of ipsc to guide Precision Medicine for NASH. David Goldman (USA) 03:20-03:50 pm Discussion 03:50-04:15 pm COFFEE BREAK AND POSTERS 04:15-05:45 pm SESSION 5 TECHNOLOGIC INNOVATIONS IN NASH Chairs: Jean-Pierre Bronowicki (France) and Frank Tacke (Germany) 04:15-04:35 pm Radiomics and imaging inflammation in solid organs. Richard Ehman (USA) 04:35-04:55 pm The protease signature of NASH. Gabe Kwong (USA) 04:55-05:15 pm Gut-based immunotherapy - implications for NASH. Yaron Ilan (Israel) 05:15-05:45 pm Discussion 05:45-06:00 pm POSTER AWARDS
FRIDAY, JULY 6, 2018 08:00-08:30 am WELCOME DESK OPENING 08:30-10:20 am SESSION 6 NAFLD AND HCC Chairs: Stanislas Pol (France) and Manuel Romero-Gómez (Spain) 08:30-08:50 am Clinical and Pathological characteristics of steatohepatitis HCC. Pierre Bedossa (France) 08:50-09:10 am Immune mechanisms in the genesis of HCC due to NASH. Frank Tacke (Germany) 09:10-09:30 am Epigenetic basis for NASH associated HCC. Igor Pogribny (USA) 09:30-09:50 am How will new therapies affect HCC development? Scott Friedman (USA) 09:50-10:20 am Discussion 10:20-10:40 am COFFEE BREAK 10:40-12:00 pm SESSION 7 PATIENT CENTERED APPROACH TO NASH Chairs: Mohammad Siddiqui (USA) and Zobair Younossi (USA) 10:40-11:00 am Development of a patient reported outcomes instrument for NASH that meets regulatory standards. Maria Magdalena Balp (United Kingdom) 11:00-11:20 am The science and art of patient-engaged trial design. Donna Cryer (USA) 11:20-11:40 am The burden of cirrhosis on their caregivers. Jasmohan Bajaj (USA) 11:40-12:00 pm Discussion 12:00-12:30 pm SESSION 8 REGULATORY LANDSCAPE Chair: Lawrence Serfaty (France) 12:00-12:20 pm Regulatory Update. Veronica Miller (USA) 12:20-12:30 pm Discussion
12:30-02:00 pm GROUP 1: GROUP 2: GROUP 3: GROUP 4: LUNCH BREAKOUT SESSION Epidemic of NAFLD in US and EU: is disease-related morbi/mortality overestimated? Philippe Mathurin (France) and Zobair Younossi (USA) Screening of HCC : can we assess the risk in non cirrhotic patients? Fabio Marra (Italy) and Valérie Paradis (France) Epigenetic mechanisms as driver of disease inheritance and disease progression. Massimo Levrero (France) and Pierre-Emmanuel Rautou (France) Weight loss: pharmacological and non-pharmacological interventions. Guillaume Lassailly (France) and Manuel Romero-Gómez (Spain) 02:00-03:00 pm SESSION 9 TRIAL DESIGN Chairs: Veronica Miller (USA) and Arun Sanyal (USA) 02:00-02:20 pm Master - protocols in NASH - challenges and opportunities. Raluca Pais (France) 02:20-02:40 pm Learning from placebo responses in current trials to improve future trial design. Quentin Anstee (United Kingdom) 02:40-03:00 pm Discussion 03:00-04:30 pm SESSION 10 ROUND TABLE Chairs: Arun Sanyal (USA) and Lawrence Serfaty (France) 03:00-04:30 pm Building synergy between patient advocacy and drug development for NASH. Panelists: Quentin Anstee (United Kingdom), Donna Cryer (USA), Dean Hum (France), Omoro Omoighe (USA), Manuel Romero-Gómez (Spain), Aldo Trylesinski (United Kingdom), EU patient representative (name TBC) 04:30 pm Concluding remarks Arun Sanyal (USA)
FACULTY 2018 ANSTEE Quentin BAJAJ Jasmohan BEDOSSA Pierre BALP Magdalena BRONOWICKI Jean-Pierre CARIOU Bertrand CRYER Donna DABBAGH Karim DAHLQVIST LEINHARD Olof DUFOUR Jean-François EHMAN Richard FRIEDMAN Scott GOLDMAN David HUM Dean ILAN Yaron KWONG Gabe LASSAILLY Guillaume LAVINE Joel LEVRERO Massimo MARCELLIN Patrick MARRA Fabio MATHURIN Philippe MILLER Veronica OMOIGHE Omoro PAIS Raluca PARADIS Valérie PAWLOTSKY Jean-Michel POGRIBNY Igor POL Stanislas RAUTOU Pierre-Emmanuel RAZAVI Homie ROMERO-GÒMEZ Manuel SANYAL Arun SERFATY Lawrence SIDDIQUI Mohammad STAELS Bart TACKE Frank TRAUNER Michael TRYLESINSKI Aldo YOUNOSSI Zobair www.paris-nash.org
INSTITUT PASTEUR 28 Rue du Docteur Roux 75015 PARIS FRANCE Congress Secretariat TAMING HEALTHCARE 58, Bd de la République 92100 Boulogne-Billancourt +33 1 84 20 32 30 Contact: contact@paris-nash.org www.paris-nash.org